



TUPPD1-001




Predicted

Pembrolizumab




Predicted

TUPPD1-002




Predicted

Nivolumab



Predicted

TUPPD1-009



Predicted

Common PD-1
Interfaced Residues:

ASN66

TYR68

GLN75

GLU84

SER87

GLN88

LEU128